|2.||Heterozygous familial hypercholesterolaemia, or|
|3.||Mixed hyperlipidaemia when response to diet or other non-pharmacological measures alone is not adequate.|
|1.||Reduce the risk of total mortality by reducing coronary death|
|2.||Reduce the risk of non-fatal myocardial infarction|
|3.||Reduce the risk of undergoing myocardial revascularization procedures (coronary artery bypass grafting and percutaneous transluminal coronary angioplasty) and|
|4.||Slow the progression of coronary atherosclerosis.|
|1.||consume substantial amounts of alcohol and/or who have a history of liver disease|
|2.||may be predisposed to developing renal failure secondary to rhabdomyolsis such as in those with severe acute infection, hypotension, severe metabolic, endocrine or electrolyte disorders, uncontrolled seizures, major surgery or trauma. There is an increased risk of developing renal failure if rhabdomyolsis occurs.|
|3.||have severe renal impairment|
|Patients starting therapy with REDICOR should be advised of the risk of myopathy and should report promptly unexplained muscle pain, tenderness or weakness. A creatinine kinase (CK) level above 10 times the Upper Limit of Normal (ULN) in a patient, with unexplained symptoms, indicates myopathy. REDICOR should be discontinued if myopathy is diagnosed or suspected.|
|2.||Measures to reduce the risk of myopathy caused by medicine interactions|
The benefits and risks of using REDICOR concomitantly with immunosuppresants, fibrates or lipid lowering doses of niacin should be carefully considered and the dose of REDICOR should generally not exceed 10 mg/day. Concomitant administration with cyclosporine, itraconazole, ketoconazole, erythromycin, clarithromycin, HIV-protease inhibitors and nefazodone, is not recommended.
In patients receiving cyclosporine, REDICOR should be temporarily discontinued if systemic azole derivative-antifungal therapy is required.